/
Oncology
Transitional Cell Carcinoma
7
Pipeline Programs↗
3
Active Trials↗
8
Companies Involved↗
Transitional Cell Carcinoma is an early-stage landscape with 7 programs across 8 companies. The most active players are AstraZeneca, Steba Biotech S.A., Roche. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 21
Phase 34
Approved
No programs
Analysis
Modality Breakdown
6programs
Small molecule350%
Monoclonal antibody233%
Protein / enzyme117%
Modality classified for 100% of 7 pipeline programs.
Analysis
Trial Status
38
clinical trials
Completed28 · 74%
Terminated3 · 8%
Active, not recruiting2 · 5%
Unknown status2 · 5%
Withdrawn2 · 5%
Recruiting1 · 3%
Clinical Trials
Trial Activity
38 trials
Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Completed·—·Phase 1·NCT01844947·22 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)